Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors

Cancer Discovery

Volumn 3, Issue 1, 2013, Pages 68-81

  Jaspers, Janneke E ^a   Kersbergen, Ariena ^a   Boon, Ute ^a   Sol, Wendy ^a   Van Deemter, Liesbeth ^a   Zander, Serge A ^a   Drost, Rinske ^a   Wientjens, Ellen ^a   Ji, Jiuping ^b   Aly, Amal ^d   Doroshow, James H ^c   Cranston, Aaron ^e,g   Martin, Niall M B ^e,h   Lau, Alan ^f   O'Connor, Mark J ^f   Ganesan, Shridar ^d   Borst, Piet ^a   Jonkers, Jos ^a   Rottenberg, Sven ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e KuDOS Pharmaceuticals   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

^g Precos Ltd In vivo services   (United Kingdom)

^h Babraham Research Campus Babraham   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2461; BRCA1 PROTEIN; CISPLATIN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN P53; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RECURRENCE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA REPAIR; DNA SEQUENCE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HOMOLOGOUS RECOMBINATION; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEFECIENCY; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MUTATION; P-GLYCOPROTEIN; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84872837247     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0049     Document Type: Article

References (40)

1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917.
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
3. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-8115.
4. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
5. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
7. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.
8. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cran-ston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fl uorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-6591.
9. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-17084.
10. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-244.
11. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007;104:12111-12116.
12. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-12122.
13. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012;2:120066.
14. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011;20:797-809.
15. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine D A, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-1115.
16. Sakai W, Swisher EM, K arlan BY, Agar wal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-1120.
17. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29: 3008-3015.
18. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68:2581-2586.
19. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit J J, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-4033.
20. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
21. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-695.
22. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-254.
23. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010;70:1700-1710.
24. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
25. Huertas P, Cortes-Ledesma F, Sartori AA, Aguilera A, Jackson SP. CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature 2008;455:689-692.
26. Huertas P, Jackson SP. Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem 2009;284:9558-9565.
27. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 2009;459:460-463.
28. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5:387-393.
29. Bunting SF, Callen E, Kozak ML, Kim JM, Wong N, Lopez-Contreras AJ, et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 2012;46:125-135.
30. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51- BRCA1/2. Cancer Cell 2012;22:106-116.
31. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-262.
32. Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, Hiom K, et al. BRCA1-independent ubiquitination of FANCD2. Mol Cell 2003;12:247-254.
33. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-3411.
34. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-94.
35. Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispons 2011;39:1161-1169.
36. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 29: 2011(suppl; abstr 5003).
37. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
38. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 2008;14:6877-6885.
39. National Cancer Institute Division of Cancer Treatment and Diagnosis. Available from:http://dctd.cancer.gov/ResearchResources/biomarkers/docs/par/SOP340520_Biopsy_Tissue.pdf.
40. National Cancer Institute Division of Cancer Treatment and Diagnosis. Available from: http://dctd.cancer.gov/ResearchResources/biomarkers/docs/par/SOP340505_PAR_IA.pdf.